Back to all webinars
Targeting relapsed/refractory follicular lymphoma: The dawn of a new era?
Christian Buske, Wojciech Jurczak and Rebecca Auer explore the current treatment landscape for R/R FL and consider how new targeted and cellular therapies may transform patient outcomes.
Speakers
Treatment guidelines and challenges in the treatment of R/R FL
No entries
Current management of R/R FL
Fast-forward to:
Current therapies for R/R FL
6544fbbe860023057552bcc0
GADOLIN study: Obinutuzumab with and without bendamustine
6544fc49860023057552bcdf
AUGMENT study: R² vs. R-placebo in R/R iNHL
6544fc9fe3ec72058294f255
MAGNIFY Phase IIIb study: R² induction followed by R² vs. R maintenance
6544fce3860023057552bcf9
Radioimmunotherapy in FL
6544fe95e3ec72058294f27b
Idelalisib in double refractory iNHL
6544ffc7e3ec72058294f28a
CAR-T cells and bispecific mAbs
654500e9e3ec72058294f29c
Mosunetuzumab: A bispecific mAb for the treatment of R/R FL
65450246e3ec72058294f2aa
CAR-T cell therapy: The TRANSCEND FL study of Liso-cel in ≥2L FL
65450662e3ec72058294f2da
Therapeutic innovations in R/R FL
Fast-forward to:
Clinical trial landscape for R/R FL
65450760e3ec72058294f2e9
Current data with bispecific antibodies in R/R FL
654507f5e3ec72058294f300
Ongoing trials with mosunetuzumab combinations in R/R FL
65450853860023057552bd82
Glofitamab with/without obinutuzumab in R/R FL
6545088f860023057552bd91
Phase III trials with epcoritamab combinations in R/R FL
6545094de3ec72058294f338
BTK inhibitors in R/R FL
654509a9860023057552bdbb
Zanubrutinib with obinutuzumab in R/R FL: ROSEWOOD (Phase II) and MAHOGANY (Phase III)
65450add860023057552bdcc
Non-covalent BTKis and BTK degraders in R/R FL
65450b8f860023057552bded
PI3K inhibition in R/R FL
65450bde860023057552bdff
Audience Q&A
Fast-forward to:
What is the current state-of-the-art for response prognostics in FL?
6544f82de3ec72058294f1e0
Is T-cell exhaustion an issue in FL?
6544f899e3ec72058294f1f3
Which individual patient characteristics can be used to guide treatment selection and how should treatment modalities be sequenced?
6544f929e3ec72058294f203
Given the adverse-event profile of bispecific mAbs and CAR-T therapies, how are patients receiving these therapies typically managed in your country?
6544f96ce3ec72058294f214
How would the presence of cytopenias affect the treatment approach for R/R FL?
6544fa40e3ec72058294f21f
Given the promising efficacy seen with zanubrutinib and obinutuzumab in R/R FL, how do you explain the failure of ibrutinib + chemoimmunotherapy in the SELENE trial?
6544fb53e3ec72058294f22e
Summary
No entries